Affiliation: | 1. Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran;2. Molecular Immunology Research Centre, Tehran University of Medical Sciences, Tehran, Iran;3. Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran Department of Stem Cell Biology, Stem Cell Technology Research Center, Tehran, Iran;4. Department of Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran Nanotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran;5. Department of Hematology, Faculty of Medical Sciences, Tarbiat Modarres University, Tehran, Iran;6. Marquette University School of Dentistry, Milwaukee, Wisconsin |
Abstract: | Significant advances have been achieved in recent years to ameliorate rheumatoid arthritis (RA) in animal models using gene therapy approaches rather than biological treatments. Although biological agents serve as antirheumatic drugs with suppressing proinflammatory cytokine activities, they are usually accompanied by systemic immune suppression resulting from continuous or high systemic dose injections of biological agents. Therefore, gene transfer approaches have opened an interesting perspective to deliver one or multiple genes in a target-specific or inducible manner for the sustained intra-articular expression of therapeutic products. Accordingly, many studies have focused on gene transferring methods in animal models by using one of the available approaches. In this study, the important strategies used to select effective genes for RA gene therapy have been outlined. Given the work done in this field, the future looks bright for gene therapy as a new method in the clinical treatment of autoimmune diseases such as RA, and by ongoing efforts in this field, we hope to achieve feasible, safe, and effective treatment methods. |